Sponsored Links

APP Pharmaceuticals To Market Letrozole Tablets, USP In The U.S. PDF Print E-mail
Medical News - Breast Cancer
Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited (NSE: FKONCO) (BSE: 532545)...

Read more: Breast Cancer News From Medical News Today